Integrated Investment Consultants LLC Acquires Shares of 18,731 Cencora, Inc. (NYSE:COR)

Integrated Investment Consultants LLC purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 18,731 shares of the company's stock, valued at approximately $4,216,000.

A number of other institutional investors have also recently modified their holdings of COR. New Millennium Group LLC acquired a new position in shares of Cencora during the 2nd quarter worth $26,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora during the 2nd quarter worth approximately $30,000. Concord Wealth Partners acquired a new stake in shares of Cencora in the 3rd quarter worth approximately $30,000. LRI Investments LLC purchased a new position in Cencora in the 1st quarter valued at approximately $31,000. Finally, SYSTM Wealth Solutions LLC purchased a new stake in Cencora during the second quarter worth $36,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the business's stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now directly owns 285,088 shares of the company's stock, valued at approximately $67,223,750.40. The trade was a 7.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 15.80% of the stock is currently owned by corporate insiders.

Cencora Trading Up 0.9 %

COR stock traded up $2.30 during trading on Thursday, reaching $245.50. 611,199 shares of the stock traded hands, compared to its average volume of 1,402,125. The firm has a market capitalization of $48.38 billion, a PE ratio of 32.38, a P/E/G ratio of 1.60 and a beta of 0.44. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business's 50 day moving average price is $232.96 and its 200-day moving average price is $231.37. Cencora, Inc. has a 52-week low of $195.83 and a 52-week high of $251.56.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be issued a $0.55 dividend. This is a positive change from Cencora's previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a yield of 0.90%. Cencora's dividend payout ratio (DPR) is presently 29.29%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on COR shares. Leerink Partners cut their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research note on Monday, October 7th. UBS Group lifted their price objective on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Barclays increased their target price on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Robert W. Baird upped their price objective on Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Finally, Bank of America reiterated a "neutral" rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.